bs-2887R **[Primary Antibody]**

CYP2C9 Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 1559 **SWISS:** P11712

Target: CYP2C9

Immunogen: KLH conjugated synthetic peptide derived from human CYP2C9: 351-450/490.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008]

Applications: **WB** (1:500-2000)
IHC-P (1:200-800)
IHC-F (1:50-200)
IF (1:50-200)

Reactivity: Mouse (predicted: Human, Rat)

Predicted MW.: 56 kDa

Subcellular Location: Cytoplasm

VALIDATION IMAGES



Sample: Lane 1: Mouse Liver tissue lysates Lane 2: Mouse Stomach tissue lysates Primary: Anti-CYP2C9 (bs-2887R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 56 kDa Observed band size: 52 kDa



Paraformaldehyde-fixed, paraffin embedded (Mouse liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (CYP2C9) Polyclonal Antibody, Unconjugated (bs-2887R) at 1:400 overnight at 4°C, followed by a conjugated secondary antibody (sp-0023) for 20 minutes and DAB staining.

SELECTED CITATIONS

- **[IF=8.1]** Wang Yuying. et al. Chemotherapy-induced acetylation of ACLY by NAT10 promotes its nuclear accumulation and acetyl-CoA production to drive chemoresistance in hepatocellular carcinoma. CELL DEATH DIS. 2024 Jul;15(7):1-17 WB ;Mouse,Human. 39085201
- **[IF=5.17]** Zhang et al. Hyperhomocysteinemia results from and promotes hepatocellular carcinoma via CYP450 metabolism by CYP2J2 DNA methylation. (2017) Oncotarge. 8:15377-15392 WB ;Human. 28030819

- **[IF=5.275]** Kai Wang. et al. Drug-drug interactions induced by Linderane based on mechanism-based inactivation of CYP2C9 and the molecular mechanisms. Bioorg Chem. 2022 Jan;118:105478 WB ;Mouse. 34800885
- **[IF=5.324]** Wang Shanshan. et al. Gut microbiota and host cytochrome P450 characteristics in the pseudo germ-free model: co-contributors to a diverse metabolic landscape. GUT PATHOG. 2023 Dec;15(1):1-14 WB ;Rat. 36945019
- **[IF=4.15]** Jiang, Zhihui, et al. "Development of an IgY Antibody-Based Immunoassay for the Screening of the CYP2E1 Inhibitor/Enhancer from Herbal Medicines." Frontiers in Pharmacology 7 (2016): 502. WB ;Mouse. 28066249